

BIOGRAPHICAL SKETCH

NAME Kunzmann, Volker	POSITION TITLE Vice Chair, Full Professor, Department of Medical Oncology/Hematology Comprehensive Cancer Center Mainfranken, University of Wuerzburg, Germany		
EDUCATION/TRAINING			
INSTITUTION AND LOCATION	DEGREE	MM/YY	FIELD OF STUDY
University of Freiburg (Germany) University of Wuerzburg (Germany)	M.D. Residency, Board Certif.	09/1989 – 07/1996 08/1996 – 04/2005	Medicine Internal Medicine and Oncology/Hematology Oncology/Immunology Medical Oncology/ Cancer immunotherapy/ GI Tumors
University of Wuerzburg (Germany) University of Wuerzburg (Germany)	Habilitation Full professorship	05/2005 – 03/2007 since 2011	

A. Personal statement

Our group is interested in improvement of therapeutic approaches in GI cancers and establishment of innovative prognostic and predictive biomarker for tumor response, especially for cancer immunotherapy.

I gained large experience in treatment and performing correlative studies in numerous tumor entities, especially GI tumors. In addition to a long time experience in translational research including preclinical and clinical studies (Phase I-III), I have experience in designing, maintaining and publishing multi-center trials.

B. Positions and Honors

Positions and Employment

1992-1993:	Trinational PhD training programme in course of the EUCOR-Project (Ph.D. programme of the European confederation of the Upper Rhine Universities: Basel/Switzerland, Freiburg/ Germany, Straßburg/ France)
1993-1996:	Continuing medical training at the Universities of Freiburg, Basel and Wuerzburg
1994:	USMLE (United States Medical Licensing Examination) Step 1
1995:	Second German Clinical Board Examination and USMLE Step 2
1995-1996:	Clinical training oncology at MD Anderson Cancer Center/Houston/USA
1996:	Third German clinical Board Examination
1997:	Thesis (Prof. M. Wilhelm, Wuerzburg) and Full License to practice medicine
1996-2003:	Postgraduate medical training at the Department of Internal Medicine (Medizinische Poliklinik), University of Würzburg (Director: Prof. Dr. K. Wilms) and research fellow in the Laboratory for Clinical Immunology
2003:	Board examination for “Internal Medicine”
2004:	Board examination for “Hematology/Medical Oncology”
2007:	Board examination for “Quality management”
2007:	ESMO (European School of Medical Oncology) Board Examinations (renewed in 2020)
Since 2008:	Head of the Interdisciplinary Oncology Outpatient Treatment Center (IOT) and Clinical Care Committee Member of the Comprehensive Cancer Center Mainfranken (CCCM)
Since 2011:	Professor of Medical Oncology and Head of the Department of Medical Oncology, University of Wuerzburg
Since 2012:	Full member German Task force “Pancreatic cancer” (AIO)

Other Experience and Professional Memberships

2005-present	Reviewer for Blood, Immunology, Journal of Immunology, J Immunotherapy, J Clin Oncology, Annals of Oncology, Lancet Oncology
2005-present	Member of German/Swiss/Austrian Society of Hematology and Oncology
2008-present	Member of the European Society of Medical Oncology (ESMO)
2008-present	Member of the Arbeitsgemeinschaft Internistische Onkologie (German Society of Medical Oncology)
2009-present	Member of the American Society of Oncology (ASCO)

C. Selected Peer-reviewed Publications (Selected from 93 peer-reviewed publications)

1. Kunzmann V, Bauer E, Wilhelm M. gamma/delta T cell stimulation by pamidronate . **N Engl J Med** 1999; 340: 737-738
2. Wilhelm M & Kunzmann V, Eckstein S, et al. gamma/delta T cells for Immune Therapy of Patients with Lymphoid Malignancies. **Blood**. 2003; 102:200-6
3. Kunzmann V, Wilhelm M. Adjuvant zoledronic acid for breast cancer: mechanism of action? **Lancet Oncol**. 2011; 12(11):991-2.
4. Wilhelm M, Smetak M, Schaefer-Eckart K, Kimmel B, Birkmann J, Einsele H, Kunzmann V. Successful adoptive transfer and in vivo expansion of haploidentical $\gamma\delta$ T cells. **J Transl Med**. 2014 15;12:45.
5. Goldstein D, El-Maraghi RH, Hammel P, Heinemann V, Kunzmann et al. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. **J Natl Cancer Inst**. 2015 Jan 31;107(2).
6. Kunzmann V, Ramanathan RK, Goldstein D, et al. Tumor Reduction in Primary and Metastatic Pancreatic Cancer Lesions With nab-Paclitaxel and Gemcitabine: An Exploratory Analysis From a Phase 3 Study. **Pancreas**. 2017; 46:203-208
7. Shitara K, Özgüroğlu M, Bang et al; KEYNOTE-061 investigators. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. **Lancet** 2018; 392(10142):123-133
8. Schuster SJ, Bishop MR, Tam CS, et al; JULIET Investigators. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. **N Engl J Med**. 2019;380:45-56.
9. Kunzmann V, Siveke JT, Algül H, et al.; German Pancreatic Cancer Working Group (AIO-PAK) and NEOLAP investigators. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. **Lancet GH** 2021;6:128-138

D. Research Support relevant to the current application

Ongoing Research Support

since 1995	Continuous research on function and specificity of human $\gamma\delta$ T-cells, GI cancer and cancer immunotherapy (supported by Deutsche Krebshilfe, DFG, EU grants and Grants of the IZKF)
since 2001	Continuous research and participation in clinical studies in GI Oncology and Cancer immunotherapy. Principal Investigator of Phase I-III clinical trials (> 50)